Komori
Nippon Shinyaku (4516) · InitiativeFirst stated

ACT-064992D (Yubanshi): preparing for approval and launch and providing information jointly

First written in FY2025-H1. . Latest entry: FY2025-H1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
ACT-064992D (Yubansi) approval and launch preparationsA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2025-H1First statedAnnual report

    「• For ACT-064992D (product name: Yubanshi® combination tablets; generic names: macitentan/tadalafil), Janssen Pharmaceutical K.K. obtained manufacturing and marketing approval in September 2024 for pulmonary arterial hypertension and is currently preparing for launch. We will conduct information-provision activities jointly with Janssen Pharmaceutical K.K.」

    For ACT-064992D (Yubanshi), we disclosed for the first time Janssen Pharmaceutical K.K.'s receipt of manufacturing and marketing approval in September 2024, launch preparations and joint information-provision activities.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Nippon Shinyaku's next results are scheduled for 2026-11-13. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.